Search

Your search keyword '"Nadia E. Aikawa"' showing total 187 results

Search Constraints

Start Over You searched for: Author "Nadia E. Aikawa" Remove constraint Author: "Nadia E. Aikawa"
187 results on '"Nadia E. Aikawa"'

Search Results

1. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients

2. Food consumption based on processing level (according to Nova system) during the COVID-19 pandemic among adolescents with immunocompromised conditions: a case-control study

3. Poor Sleep quality and health-related quality of life impact in adolescents with and without chronic immunosuppressive conditions during COVID-19 quarantine

4. Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: A prospective study in a Latin American tertiary hospital

5. Lower genital tract infections in young female juvenile idiopathic arthritis patients

6. Autoimmune hepatitis in 847 childhood-onset systemic lupus erythematosus population: a multicentric cohort study

7. Diffuse alveolar hemorrhage in childhood-onset systemic lupus erythematosus: a severe disease flare with serious outcome

8. Juvenile dermatomyositis: is periodontal disease associated with dyslipidemia?

9. Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two

10. Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy

11. Substance use and sexual function in juvenile idiopathic arthritis

13. Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy

14. Risk factors for mortality in 1528 Brazilian childhood-onset systemic lupus erythematosus patients

15. Physical Activity: A Strategy to Improve Antibody Response to a SARS-CoV-2 Vaccine Booster Dose in Patients With Autoimmune Rheumatic Diseases

17. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine

18. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study

19. Social impact of disease parameters and damage accrual in adult Brazilian patients with childhood-onset Systemic Lupus Erythematosus

20. Impact of Distinct Therapies on Antibody Response to<scp>SARS‐CoV</scp>‐2 Vaccine in Systemic Lupus Erythematosus

21. Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients

22. Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases

23. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study

24. Emotional, hyperactivity and inattention problems in adolescents with immunocompromising chronic diseases during the COVID-19 pandemic

25. 2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus

26. Home-based exercise program for adolescents with juvenile dermatomyositis quarantined during COVID-19 pandemic: a mixed methods study

27. Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients

28. Mental Health Impact in Latin American Pediatric Rheumatologists During the COVID-19 Pandemic

29. The influence of environmental factors related to Juvenile Dermatomyositis (JDM), its course and refractoriness to treatment

30. Is positron emission tomography/magnetic resonance imaging a reliable tool for detecting vascular activity in treated childhood-onset Takayasu’s arteritis? A multicentre study

31. One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels

32. Laboratory-confirmed pediatric COVID-19 in patients with rheumatic diseases: A case series in a tertiary hospital

33. Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2–3 mg/kg/day): 12-month prospective randomized controlled trial

34. Chronic kidney disease in patients with childhood-onset systemic lupus erythematosus

35. Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis

36. Strong response after 4th dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine

37. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose

38. Effect of an Exercise Bout Prior to the Booster Dose of an Inactivated SARS-CoV-2 Vaccine on Immunogenicity in Immunocompromised Patients

39. Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: A prospective study in a Latin American tertiary hospital

40. A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE

41. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients

42. The new 2019-EULAR/ACR classification criteria specific domains at diagnosis can predict damage accrual in 670 childhood-onset systemic lupus erythematosus patients

43. Poor Sleep quality and health-related quality of life impact in adolescents with and without chronic immunosuppressive conditions during COVID-19 quarantine

44. Immunogenicity, Safety and Antiphospholipid Antibodies After SARS-CoV-2 Vaccine in Patients With Primary Antiphospholipid Syndrome

45. Intermittent abdominal pain in IgA vasculitis

46. Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity

47. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2

48. Heart function in juvenile idiopathic arthritis patients: A biventricular two-dimensional speckle-tracking echocardiography study

49. Lupus nephritis-related issues during COVID-19 pandemic quarantine

50. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching

Catalog

Books, media, physical & digital resources